Paladin CEO still shopping for deals; Bayer chief declares 6% Japanese growth goal;

@FiercePharma: Drugmakers aren't the only ones upset about German pricing policies More | Follow @FiercePharma

> Paladin Labs says it is still scouting for acquisitions after its hostile bid for Afexa failed in the face of a higher offer from Valeant Pharmaceuticals. Story

> Bayer CEO Marijn Dekkers told a Tokyo audience that his company plans to grow 6% per year through 2015, to reach 2.4 billion euros in Japanese sales. Report

> The U.K.'s cost-effectiveness watchdog has been asked to review the implications of broader off-label prescribing among National Health Service doctors. Report

> Pozen is scouting for a pharma partner to help market its in-development heart drug. Item

> Omnicare, the pharmacy services firm, extended its hostile bid for PharMerica by two months. More

> Drug wholesaler AmerisourceBergen agreed to buy patient access and reimbursement services firm TheraCom for $250 million. Article

Biotech News

@FierceBiotech: People with Huntington's overexpress a gene call H2AFY. Biomarker could eventually help gauge effectiveness of new drugs. Piece | Follow @FierceBiotech

@ JohnCFierce: "We're going after a new area of biology," says Agios CEO Schenkein. "And we're going after it hard." Article | Follow @JohnCFierce

@RyanMFierce: I hope this approach to combating brain cancer works as well in man as it did in mice. Story | Follow @RyanMFierce

@MaureenFierce: Good news and bad news: So many jobs are gone, pharma layoffs dwindle. Item | Follow @MaureenFierce

> Agios wins $20M haul as Celgene extends cancer development pact. News

> Detailed BG-12 data supports Biogen's blockbuster MS ambitions. Article

> BioCryst shares surge on positive IIb study for gout drug. More

Medical Device News

> Cambridge Heart reports positive results from MTWA-CAD study. Item

> Ventana wins clearance for H. pylori antibody. Report

> Interrad scores $10M in Series C. More

> FDA unveils streamlined de novo guidelines. Report

> With inexpensive materials, iPhone becomes imaging device. Story

> NEA leads $16M round for drug-eluting balloon firm. Piece

Drug Delivery News

> Probe of HIV peptide leads to drug-delivery clues. News

> Mission Pharmacal hitches onto TriLogic's delivery tech. Article

> Ultrasound-guided drug delivery gets FDA nod. Report

> Biotechs grab funds for drugs that cross brain barrier. More

> Search-and-destroy drugs attack lethal brain cancer. Story

And Finally... A new animal study hints that Alzheimer's disease might be transmissible, but much more research is needed to determine whether it can spread among humans under normal, outside-the-laboratory circumstances. News

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.